Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04601857
Title Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Taiho Oncology, Inc.
Indications

transitional cell carcinoma

Therapies

Futibatinib + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST